ASX-listed medical device company Cochlear Limited (ASX:COH) Limited provided an update on the impact of COVID-19 pandemic to its current trading conditions.
The Company disclosed that sales revenue across the business dropped by ~60% in April with cochlear as well as acoustic implants severely affected.
Cochlear implant unit sales dwindled by ~80% across developed markets, with most elective surgeries delayed across Western Europe and the United States.